You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東誠藥業(002675.SZ):氟[18F]思睿肽注射液III期臨牀試驗完成全部受試者入組

格隆匯6月13日丨東誠藥業(002675.SZ)公佈,近日,煙臺東誠藥業集團股份有限公司控股子公司煙臺藍納成生物技術股份有限公司(簡稱“藍納成”)組織開展的氟[18F]思睿肽注射液III期臨牀試驗,目前已完成全部488例受試者入組。

氟[18F]思睿肽與PSMA蛋白具有較高的特異性和親和力,可在PSMA高表達的腫瘤中高度濃聚,從而可以將氟[18F]帶至前列腺癌患者PSMA表達陽性部位,採用正電子發射斷層掃描(PET)成像技術實現診斷目的。

目前國內未有同類產品上市,國外已有同類產品上市,根據Lantheus公司的2024年度報告顯示,其產品18F-PSMA診斷藥PYLARIFY,2024年實現銷售收入11億美金。截至目前,氟[18F]思睿肽注射液項目累計已投入研發費用約1.19億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account